



Support for Title 21 CFR Part 11 and Annex 11 Compliance: Agilent Cary WinUV Pharma

White Paper

Overview

US FDA Part 11 in Title 21 of the Code of Federal Regulations (CFR), and its EU analog, Eudralex Chapter 4, Annex 11, describe the requirements for electronic records and electronic signatures for regulated pharmaceutical organizations. Released in 1997, 21 CFR Part 11 has been enforced since 1999. The intent of these guidelines is to ensure that all appropriate electronic records are attributable, legible, contemporaneous, original, accurate, and maintained with integrity.

This white paper is a resource for users of Agilent Cary WinUV Pharma (Version 4.1 and later) that couples Cary WinUV software with Spectroscopy Configuration Manager (SCM) and the Spectroscopy Database Administrator (SDA). It is the responsibility of the user and their organization to ensure that the functionalities provided by Cary WinUV with SCM/SDA are used appropriately to achieve compliant operation for laboratory data acquisition and processing. In addition to the technical controls provided by the software, the user organization must establish procedural controls—standard operating procedures (SOPs)—to address relevant nontechnical requirements. For example, controls such as internal audit programs must also be established to ensure that system operators follow the SOPs.

Appendix 1 provides a detailed description of how Cary WinUV Pharma supports users and their organizations in achieving the requirements of each section of 21 CFR Part 11 and the related sections of EU Annex 11. The descriptions assume that system access, including instrument hardware and software, is controlled by the staff responsible for the electronic records contained on the system. Thus, the system is designed as a “closed system” as defined in 21 CFR Part 11.3(b)(4).



21 CFR Part 11

21 CFR Part 11 covers three specific elements of a regulated laboratory's operation:

- Security of electronic records
- Attribution of work
- Electronic signatures (if used)

Security

Security can be interpreted as “the right people, having the right access, to the right information.” Regulated organizations must be able to both verify the identity of system users, and limit system access to trained, authorized individuals (11.10(d), (i) and (g); 11.100(b)). Because laboratory staff have different responsibilities based on their job assignments, data access must be segregated and defined such that certain users have certain types of access to certain data sets, while potentially having different access to other data sets.

“Separation of duty, as a security principle, has as its primary objective the prevention of fraud and errors. This objective is achieved by disseminating the tasks and associated privileges for a specific business process among multiple users.”

Botha, Eloff, IBM Systems Journal [1]

Attribution of work

Attribution of work refers to documenting the “who, what, when, where, and why?” of work performed. Automated audit trails independently record users’ actions, thus connecting laboratory staff to the work they perform. Audit trail entries enable staff and regulatory inspectors to reconstruct the complete history of an electronic record.

- **Who:** Clearly identifies the person responsible for the particular action that creates, modifies, or deletes a record.
- **What:** Is the action that took place, including, if applicable, the old value and the new value contained in the record.
- **When:** Unambiguously declares the date and time the action took place.
- **Where:** Clearly identifies the impacted record.
- **Why:** Explains the reason for a change to a regulated record. The reason is often selected from a list of pre-defined reasons to provide consistency and to enable searching and sorting of entries.

eSignatures

While 21 CFR Part 11 does not require the use of eSignatures, it does provide regulations for when they are used. In this case, the system must ensure that eSignatures:

- Are irrevocably linked to their respective records
- Show the full name of the signer, date, and time, as well as the meaning of, or reason for, the signature (such as review, approval, responsibility, or authorship)
- Are present whenever the signed records are displayed or printed

Appendix 1. Satisfying the Requirements Set Forth in US FDA Title 21 CFR Part 11 and Related Global Regulations Using Agilent Cary WinUV Pharma

Appendix 1 table notes

Column one

The table addresses 21 CFR Part 11 requirements in the order that they are presented in the US FDA reference document. [2] Related requirements such as those found in EU Annex 11 [3] follow each section of Part 11.

Column two

For completeness, column two lists all requirements of 21 CFR Part 11 and other related global requirements. “System” refers to the analytical system used to acquire and process data.

Most requirements are fulfilled by either technical controls (that is, software functionality) or procedural controls (that is, SOPs). Technical controls are controls provided by the software and, therefore, the software supplier, while procedural controls are the responsibility of the user organization. 21 CFR Part 11 requirements listed in bold are requirements addressed by technical controls. Other global requirements are listed in regular font. Requirements that must be addressed by procedural controls are listed in blue.

Column three

Some requirements involve both technical and procedural controls. Responsibilities for each requirement are listed in column three. “S” refers to an analytical system supplier. “U” refers to the user organization. Rows containing requirements that must be exclusively addressed by the user organization are shown in blue. Blue may also indicate technical controls the user will be responsible to implement.

Column four

If available, and where appropriate, related global requirements and comments are provided in column four.

Column five

Column five indicates with a “yes” or “no” whether the requirement can be satisfied using the technical controls provided in Cary WinUV with SCM/SDA. N/A is not applicable to the software.

Column six

Column six explains how the regulatory requirement can be satisfied using the technical controls provided by Cary WinUV with SCM/SDA. Column six also provides additional recommendations for the user organization when relevant.

1. Validation

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Part 11 11.10(a)	1.1 Is the system validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records?	S, U	<p>Required by all regulations.</p> <p>This is a typical example of shared responsibility between the system supplier and the user organization. While the user organization has ultimate responsibility for validation, some tasks can only be done, and must be delivered, by the software supplier, for example, validation activities during development and related documentation.</p> <p>第五章系统</p> <p>第十三条在计算机化系统使用之前，应当对系统全面进行测试，并确认系统可以获得预期的结果。当计算机化系统替代某一人工系统时，可采用两个系统（人工和计算机化）平行运行的方式作为测试和验证内容的一部分。</p> <p>第五章系统</p> <p>第十三条在计算机化系统使用之前，应当对系统全面进行测试，并确认系统可以获得预期的结果。当计算机化系统替代某一人工系统时，可采用两个系统（人工和计算机化）平行运行的方式作为测试和验证内容的一部分。</p>	Yes	<p>Agilent Technologies has extensively verified the performance of Agilent Cary WinUV with SCM/SDA using tests that evaluate accuracy, reliability, and consistent performance. However, the user organization is required to validate their analytical system according to regulatory expectations.</p> <p>With respect to Cary WinUV, “regulated records” are:</p> <ul style="list-style-type: none"> • Methods • Results • Associated audit trails • Electronic signatures <p>Cary WinUV with SCM/SDA check-sums these records to discover any “invalid or altered records”. If an invalid or altered record is discovered, an error is displayed, and the user is not able to open the files.</p>
Annex 11	1.2 Is infrastructure qualified?	U	Annex 11.Principle B Brazil GMP 577	N/A	Qualification of infrastructures, such as servers and networks, is the responsibility of the user organization.

2. Accurate Copies and Secure Retention and Retrieval of Records

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Part 11 11.10(b)	2.1 Is the system capable of generating accurate and complete copies of records in both human readable and electronic form suitable for inspection, review, and copying by the FDA?	S	<p>第五章系统</p> <p>第十九条以电子数据为主数据时，应当满足以下要求：</p> <p>（一）为满足质量审计的目的，存储的电子数据应当能够打印成清晰易懂的文件。</p>	Yes	Records are available printed on paper or electronically as a PDF file. The result file that includes the electronic record, data, method audit trail, operator identification, and electronic signatures can be loaded at any time using the Cary WinUV software on a client PC, as a copy of the original data for review or inspection by the FDA. “Printed” reports are traceable to the original electronic files.
Annex 11	2.2 Is it possible to obtain clear printed copies of electronically stored e-records?	S	Annex 11.8.1 Brazil GMP 583	Yes	A printout representing the electronic record is printable on paper as well as electronically as a PDF file.

2. Accurate Copies and Secure Retention and Retrieval of Records, Continued

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Brazil	2.3 Are there controls to ensure that the data backup, retrieving, and maintenance process is duly carried out?	S, U	Brazil 585.2 第五章系统 第十九条以电子数据为主数据时，应当满足以下要求： (三) 应当建立数据备份与恢复的操作规程，定期对数据备份，以保护存储的数据供将来调用。备份数据应当储存在另一个单独的、安全的地点，保存时间应当至少满足本规范中关于文件、记录保存时限的要求。	Yes	While backing up data is the responsibility of the user organization, the SCM/SDA is designed to allow back up of all relevant files.
Part 11 11.10(c)	2.4 Does the system protect records to enable their accurate and ready retrieval throughout the records retention period?	S, U	China GMP 163		All raw data, metadata, and result data generated by Cary WinUV is stored in a protected location in the SDA database. Physical security (control of physical access to workstations and servers) is the responsibility of the user organization.
Annex 11	2.5 Are data checked during the archiving period for accessibility, readability, and integrity?	U	Annex 11.17	N/A	It is the responsibility of the user organization to ensure data are checked during archival for accessibility, readability, and integrity.
Annex 11	2.6 If relevant changes are made to the system (for example, computer equipment or programs), is the ability to retrieve the data ensured and tested?	S, U	Annex 11.17	Yes	The system is designed to read data from earlier versions of Cary WinUV. The user organization is responsible for ensuring readability of this data during their implementation and validation processes.
Annex 11	2.7 Are data secured by both physical and electronic means against damage?	S, U	Annex 11.7.1 Brazil GMP 584 第五章系统 第十条系统应当安装在适当的位置，以防止外来因素干扰。 第五章系统 第十九条以电子数据为主数据时，应当满足以下要求： (二) 必须采用物理或者电子方法保证数据的安全，以防止故意或意外的损害。日常运行维护和系统发生变更（如 计算机设备或其程序）时，应当检查所存储数据的可访问性及数据完整性。	Yes	All raw data, metadata, and result data generated by the system are stored in a protected location. Physical security is the responsibility of the user organization.
Clinical guide	2.8 Are there controls implemented that allow the reconstruction of the electronic source/raw documentation for FDA's review of the (clinical) study and laboratory test results?	S	Clinical Computer Guide F2 FDA Q&As	Yes	All raw data is maintained in secure storage to allow reconstruction of laboratory test results as needed.

2. Accurate Copies and Secure Retention and Retrieval of Records, Continued

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Clinical guide	2.9 Does the information provided to FDA fully describe and explain how source/raw data were obtained and managed, and how electronic records were used to capture data?	U	Clinical Computer Guide F2 FDA Q&As	N/A	It is the responsibility of the user organization to describe how source/raw data were obtained and managed, and how electronic records were used to capture data.
Annex 11	2.10 Does the system allow performing regular backups of all relevant data?	S	Annex 11.7.1 China GMP 163 Brazil GMP 585 Part 211, 68 b	Yes	While backing up data is the responsibility of the user organization, the system is designed to allow backup of all relevant files.
Annex 11	2.11 Is the integrity and accuracy of backup data and the ability to restore the data checked, validated, and monitored periodically?	U	Annex 11.7.2 China GMP 163 Brazil GMP 585 Part 211, 68 b	N/A	It is the responsibility of the user organization to ensure the integrity and accuracy of backed-up data, and to check, validate and monitor restored data periodically.
Clinical Computer Guide	2.12 Are procedures and controls in place to prevent the altering, browsing, querying, or reporting of data through external software applications that do not enter through the protective system software?	S,U	Clinical Computer Guide E	Yes	Electronic records generated by the application are stored in a protected format that cannot be accessed by other software applications. The records are proprietary binary coded, and use a unique verification for each record to ensure no tampering has occurred. If such a record is altered through another application, it will be detected by the system when trying to read the record.
Clinical Computer Guide	2.13 Are there controls implemented to prevent, detect, and mitigate effects of computer viruses, worms, or other potentially harmful software code on study data and software?	S,U	Clinical Computer Guide F	Yes	Agilent has tested Cary WinUV with SCM/SDA in conjunction with industry standard antivirus applications. However, it is the responsibility of the user organization to implement antivirus software.

3. Authorized Access to Systems, Functions, and Data

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Part 11 11.10(d)	3.1 Is system access limited to authorized persons?	S, U	China GMP 183 163 Brazil GMP 579, ICH Q7.5.43	Yes	The system has restricted access only available for users who have been explicitly added by the system administrators. Each user is identified by a unique ID and password combination. Entry of both is required to access the system.
	3.2 Is each user clearly identified, for example, through his/her own user ID and Password?	S, U	Several Warning Letters	Yes	Each user is identified by a unique ID and password combination. Entry of both is required to access the system.
Clinical	3.3 Are there controls to maintain a cumulative record that indicates, for any point in time, the names of authorized personnel, their titles, and a description of their access privileges?	S, U	Clinical Computer Guide 4	Yes	The application records user details such as full name, description/title, and access privileges. Access privileges are set in the application, and any changes are recorded in the activity log. Reports are available that show users' individual and inherited group privileges. These reports are useful for organizations required to perform periodic security reviews.

4. Electronic Audit Trail

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Part 11 11.10(e)	4.1 Is there a secure, computer-generated, time-stamped audit trail to independently record the date and time of operator entries and actions that create, modify, or delete electronic records?	S	China GMP 163 第五章系统 第十六条计算机化系统应当记录输入或确认关键数据人员的身份。只有经授权人员，方可修改已输入的数据。每次修改一个已输入的关键数据均应当经过批准，并应当记录更改数据的理由。应当根据风险评估的结果，考虑在计算机化系统中建立一个数据审计跟踪系统，用于记录数据的输入和修改。	Yes	All user activities are recorded in secure, computer-generated, time-stamped audit trails. Audit trails are created for all methods and results.
FDA GLP	4.2 Does the audit trail record who has made which changes, when and why?	S	FDA 21 CFF 58.130 e Clinical Computer Guide 2 Clinical Source Data 3	Yes	The audit trail includes the operator, date and time of the change, and the before and after values, together with why the change was made.
Annex 11	4.3 Can the system generate printouts indicating if any of the e-records have been changed since the original entry?	S	Annex 11, 8.2	Yes	When changes to an application file occur, an entry in the audit trail is generated documenting that the original file has been changed, the time and date, and the operator. The audit trail can be viewed and printed from within the application.
FDA GMP	4.4 Does the audit trail include any modifications to an established method employed in testing? 4.5 Do such records include the reason for the modification? 4.6 Is the audit trail function configured to be always on and can it not be switched off by system users?	S S,U	Part 211.194 8b Warning Letter	Yes Yes	Methods have full audit trails, including the reason for any method modification. Generation of the audit trail is computer generated, always on, and automatically saved with the relevant application file.
Annex 11	4.7 Is audit trail available in a generally intelligible form for regular review? 4.8 Can audit trail contents be configured such that only relevant activities are recorded for realistic and meaningful review of audit trail information?	S S	Annex 11, 9 Implicitly required by Annex 11 and many warning letters related to review of audit trail.	Yes Yes	It is possible to view the audit trail of an electronic record at any time by a user with appropriate privileges and using the application software. Audit trail contents are nonconfigurable and noneditable by the user. Within the SCM, system audit trail content can be filtered prior to displaying its contents to address user preferences for reviewing the information.
Part 11 11.10(e)	4.9 Is previously recorded information left unchanged when records are changed?	S		Yes	Previously recorded information is saved with a unique filename associated with only that electronic record. Any subsequent changes require a new filename for the electronic record.
Part 11 11.10(e)	4.10 Is audit trail documentation retained for a period at least as long as that required for the subject electronic record?	S,U		Yes	The audit trail is automatically saved with the associated electronic record, and cannot be separated from it.
Part 11 11.10(e)	4.11 Is audit trail available for review and copying by the FDA?	S		Yes	Audit trails can be reviewed and printed.
Annex 11	4.12 Is it possible to obtain clear printed copies of electronically stored e-records (for example, e-audit trail)?	S	Annex 11, 8.1	Yes	Audit trails can be reviewed and printed.

5. Operational and Device Checks

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Part 11 11.10(f)	5.1 Are there operational system checks to enforce permitted sequencing of steps and events, if required?	S		Yes	When a sequencing of events is required, system checks enforce it. If only approved methods are to be used in QA/QC, this can be achieved by restricting user access to the approved methods stored in the SDA database. Within Cary WinUV, sequencing of events are enforced with regards to electronic records in that the software ensures that required settings and facilities are available before allowing data to be collected and analyzed, or ensuring files are saved before the application is closed.
Part 11 11.10(g)	5.2 Are there authority checks to ensure that only authorized individuals can use the system, electronically sign a record, access the operation or computer system input or output device, alter a record, or perform the operation at hand?	S	Part 211, 68 b	Yes	The system supports configurable user roles that control system access at a detailed level. Access can be segregated and defined such that certain users have certain specific types of access to certain specific types of files while having different access to other types of files.
	5.3 Is the system designed to record the identity of operators entering, changing, confirming or deleting data including date and time?	S	Annex 11, 12.4	Yes	The identity of operators taking action in the system is recorded in the both the audit trail and activity log.
Part 11 11.10(h)	5.4 Does the system allow device checks to determine, as appropriate, the validity of the source of data input or operational instruction?	S	There are two equally valid interpretations of this requirement. Systems should be designed such that: Proper communication is confirmed between the computer and the "source" of data input (that is, the instrument) prior to transmission of instructions to or data from the "source." Regulated records created by the system must unambiguously indicate the "source" of the data (that is, which instrument or component generated the data.)	Yes	1. The system is designed to continually ensure a valid connection between the instrument and the computer workstation. 2. The system recognizes instrument models and serial numbers and records these in the audit trail as the data source.
Part 11 11.10(i)	5.5 Is there documented evidence that persons who develop, maintain, or use electronic record/electronic signature systems have the education, training, and experience to perform their assigned tasks?	U	China GMP 18 Brazil 571	N/A	It is the responsibility of the user organization to maintain documented evidence that the persons who develop, maintain, or use electronic record and electronic signature systems have the education, training, and experience needed to perform these tasks. Relevant Agilent Technologies employees have received training in relevant aspects of data integrity.
Part 11 11.10(j)	5.6 Is there a written policy that holds individuals accountable and responsible for actions initiated under their electronic signatures, in order to determine record and signature falsification?	U		N/A	It is the responsibility of the user organization to establish a written policy (SOP) that holds staff responsible for the actions initiated under their electronic signatures.

5. Operational and Device Checks, Continued

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
	5.7 Have employees been trained on this procedure?	U	Implied requirement of Part 11 11.10(j)	N/A	It is the responsibility of the user organization to train their staff.
Part 11 11.10(k)	5.8 Are there appropriate controls over systems documentation, including: (1) Adequate controls over the distribution of, access to, and use of documentation for system operation and maintenance? (2) Revision and change control procedures to maintain an audit trail that documents time-sequenced development and modification of systems documentation?	U	China GMP 161 第五章系统 第十一条应当有详细阐述系统的文件（必要时，要有图纸），并须及时更新。此文件应当详细描述系统的工作原理、目的、安全措施和适用范围、计算机运行方式的主要特征，以及如何与其他系统和程序相接。	N/A	It is the responsibility of the user organization to establish systems documentation.
Part 11 11.10(i)	5.9 Are there revision and change control procedures to maintain an audit trail that documents time-sequenced development and modification of system documentation?	S, U	第五章系统 第十七条计算机化系统的变更应当根据预定的操作规程进行，操作规程应当包括评估、验证、审核、批准和实施变更等规定。计算机化系统的变更，应经过该部分计算机化系统相关责任人员的同意，变更情况应有记录。主要变更应当经过验证。	Yes	Agilent maintains development and testing documentation for Cary WinUV Pharma. Upon request, this documentation is available for user review. The user organization is expected to maintain documentation of their system and associated changes <i>in situ</i> .

6. Data Integrity, Date and Time Accuracy

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Annex 11	6.1 Do computerized systems that exchange data electronically with other systems include appropriate built-in checks for the correct and secure entry and processing of data?	S	Annex 11.5	N/A	There is no such implementation in the system.
Annex 11	6.2 Is there an additional check on the accuracy of the data? (This check may be done by a second operator or by validated electronic means.)	S,U	Annex 11-6 Brazil GMP 580 ICHQ7-5.45 第五章系统 第十五条当人工输入关键数据时（例如在称重过程中输入物料的重量和批号），应当复核输入记录以确保其准确性。这个复核可以由另外一个操作人员完成，或采用经验证的电子方式。必要时，系统应当设置复核功能，确保数据输入的准确性和数据处理过程的正确性。	N/A	There is no such implementation in the system.
Clinical Computer Guide	6.3 Are controls established to ensure that the system's date and time are correct?	S, U	Clinical Computer Guide D.3	Yes	This is configured in and controlled by the operating system.
Clinical Computer Guide	6.4 Can date or time only be changed by authorized personnel, and is such personnel notified if a system date or time discrepancy is detected?	S	Clinical Computer Guide D.3	Yes	The time and date settings can only be changed in the operating system settings by a system administrator.
Clinical Computer Guide I	6.5 Are time stamps with a clear understanding of the time zone reference used implemented for systems that span different time zones?	S, U	Clinical Computer Guide D.3	Yes	Time stamps are performed using Greenwich Mean Time (GMT).

7. Control for Open Systems (only applicable for open systems)

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Part 11 11.30	7.1 Are there procedures and controls designed to ensure the authenticity, integrity, and, as appropriate, the confidentiality of electronic records from the point of their creation to the point of their receipt?	S,U		N/A	The system is not intended to be deployed as an "open" system as per 21 CFR Part 11.3(b) (9).
Part 11 11.30	7.2 Are there additional measures such as document encryption and use of appropriate digital signature standards to ensure, as necessary under the circumstances, record authenticity, integrity, and confidentiality?	S		N/A	The system is not intended to be deployed as an "open" system as per 21 CFR Part 11.3(b) (9).

8. Electronic Signatures – Signature Manifestation and Signature/Record Linking

Part 11 and others	Requirement	S, U	Other associated regulations or comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Annex 11	8.1 When electronic signatures are used, do they have the same impact as handwritten signatures within the boundaries of the company? Are they permanently linked to their respective record? Do they include the time and date that they were applied?	S,U	Annex 11.14 ICH Q7.6.18 第五章系统 第二十三条电子数据可以采用电子签名的方式，电子签名应当遵循相应法律法规的要求。	Yes	The user organization must establish the legal impact of electronic signatures. Signatures are permanently linked to their respective records, which can include the final report. Signed electronic records show the name of the signer, and date and time the signature was executed, and the meaning of the signature.
Part 11 11.50 (a)	8.2 Do signed electronic records contain information associated with the signing that clearly indicates all of the following: (1) The printed name of the signer? (2) The date and time when the signature was executed? (3) The meaning (such as review, approval, responsibility, or authorship) associated with the signature?	S		Yes	The application produces a report that indicates: 1) The full name of the signer 2) The date and time the signature was executed 3) A comment that is compulsorily entered to indicate the reason for the signature.
Part 11 11.50 (b)	8.3 Are the items identified in paragraphs (a)(1), (a)(2), and (a)(3) of this section subject to the same controls as for electronic records and are they included as part of any human readable form of the electronic record (such as electronic display or printout)?	S		Yes	All electronic signature components are displayed and printed.
Part 11 11.70	8.4 Are electronic signatures and handwritten signatures linked to their respective electronic records to ensure that the signatures cannot be excised, copied, or otherwise transferred to falsify an electronic record by ordinary means?	S		Yes	Electronic signatures are embedded in the result file, and cannot be transferred from one record or file to another.
Part 11 Preamble	8.5 Is there a user specific automatic inactivity disconnect measure that would “de-log” the user if no entries or actions were taken within a fixed short timeframe?	S	Part 11 Preamble section 124	Yes	Automatic session locking enables the user organization to configure a time after which the user is automatically logged out.

9. Electronic Signatures General Requirements and Signature Components and Controls

Part 11 and others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Part 11 11.100(a)	9.1 Is each electronic signature unique to one individual and not reused by, or reassigned to, anyone else?	S,U		Yes	Each user has a unique login and a unique signature that cannot be used by another user.
Part 11 11.100(b)	9.2 Does the organization verify the identity of the individual before the organization establishes, assigns, certifies, or otherwise sanctions an individual's electronic signature, or any element of such electronic signature?	U		N/A	It is the responsibility of the user organization to verify the identity of staff before it establishes, assigns, certifies, or otherwise sanctions an individual's electronic signature, or any element of such electronic signature.
Part 11 11.100 (c)	9.3 Are persons using electronic signatures, prior to or at the time of such use, certified to the agency that the electronic signatures in their system, used on or after August 20, 1997, are intended to be the legally binding equivalent of traditional handwritten signatures?	U		N/A	It is the responsibility of the user organization to verify that staff using electronic signatures meet these requirements.
	9.4 Do persons using electronic signatures, upon agency request, provide additional certification or testimony that a specific electronic signature is the legally binding equivalent of the signer's handwritten signature?				
Part 11 11.200(a) (1)	9.5 Do electronic signatures that are not based upon biometrics employ at least two distinct identification components such as an identification code and password?	S, U		Yes	Both identification (user identification) and password are required to make an electronic signature.
Part 11 11.200(a) (1) (i)	9.6 When an individual executes a series of signings during a single, continuous period of controlled system access, is the first signing executed using all electronic signature components?	S		Yes	Both identification (user identification) and password are required to make all electronic signatures.
Part 11 11.200(a) (1) (i)	9.7 When an individual executes a series of signings during a single, continuous period of controlled system access, are subsequent signings executed using at least one electronic signature component that is only executable by, and designed to be used only by, the individual?	S		Yes	Both identification (user identification) and password are required to make all electronic signatures.
Part 11 11.200(a) (1) (ii)	9.8 When an individual executes one or more signings not performed during a single, continuous period of controlled system access, is each signing executed using all of the electronic signature components?	S		Yes	Both identification (user identification) and password are required to make all electronic signatures.
Part 11 11.200(a) (2)	9.9 Are controls in place to ensure that electronic signatures that are not based upon biometrics are used only by their genuine owners?	S		Yes	Both identification (user identification) and password are required to make all electronic signatures.
Part 11 11.200(a) (3)	9.10 Are the electronic signatures be administered and executed to ensure that attempted use of an individual's electronic signature by anyone other than its genuine owner requires collaboration of two or more individuals?	S, U		Yes	Misuse of electronic signatures by anyone other than the owner would require intentional cooperation of a user and the System Administrator.
Part 11 11.200(b)	9.11 Are electronic signatures based upon biometrics designed to ensure that they cannot be used by anyone other than their genuine owners?	S		N/A	Biometric signatures are not available with this system.

10. Controls for Identification Codes and Passwords

Part 11 and others	Requirement	S, U	Other associated regulations and comments	If yes, how, specifically, is the requirement satisfied?	
				Yes/No	If no, what is the recommendation to users?
Part 11 11.300(a)	10.1 Are controls in place to maintain the uniqueness of each combined identification code and password, such that no two individuals have the same combination of identification code and password?	S, U		Yes	Each user in the system must be unique and assigned to a specific user account.
Part 11 11.300(b)	10.2 Are controls in place to ensure that identification code and password issuance are periodically checked, recalled, or revised (for example, to cover such events as password aging)?	S, U		Yes	All aspects of password administration, such as password aging, history, and minimum length can be designated within the application. The user organization should configure password expiration based on a documented risk assessment.
Part 11 11.300(c)	10.3 Are there procedures to electronically deauthorize lost, stolen, missing, or otherwise potentially compromised tokens, cards, and other devices that bear or generate identification code or password information, and to issue temporary or permanent replacements using suitable, rigorous controls?	U	第五章系统 第十四条数据的输入或修改只能由经许可的人员进行。杜绝未经许可的人员输入数据的手段有：使用钥匙、密码卡、个人密码和限制对计算机终端的访问。应当就输入和修改数据制订一个授权、取消、授权变更，以及改变个人密码的规程。必要时，应当考虑系统能记录未经许可的人员试图访问系统的行为。对于系统自身缺陷，无法实现人员控制的，必须具有书面程序，相关记录本及相关物理隔离手段，保证只有经许可的人员方能进行操作。	N/A	It is the responsibility of the user organization to establish these procedures.
Part 11 11.300(d)	10.4 Are there transaction safeguards in place to prevent unauthorized use of passwords and/or identification codes, and to detect and report in an immediate and urgent manner any attempts at their unauthorized use to the system security unit, and, as appropriate, to organizational management?	U	第五章系统 第十四条数据的输入或修改只能由经许可的人员进行。杜绝未经许可的人员输入数据的手段有：使用钥匙、密码卡、个人密码和限制对计算机终端的访问。应当就输入和修改数据制订一个授权、取消、授权变更，以及改变个人密码的规程。必要时，应当考虑系统能记录未经许可的人员试图访问系统的行为。对于系统自身缺陷，无法实现人员控制的，必须具有书面程序，相关记录本及相关物理隔离手段，保证只有经许可的人员方能进行操作。	N/A	It is the responsibility of the user organization to establish these transaction safeguards.
Part 11 11.300(e)	10.5 Are there controls for initial and periodic testing of devices, such as tokens or cards, that bear or generate identification code or password information to ensure that they function properly and have not been altered in an unauthorized manner?	U		N/A	It is the responsibility of the user organization to establish controls to test devices initially as well as periodically to ensure they function properly and have not been altered in an unauthorized manner.

11. System Development and Support

Part 11 and Others	Requirement	S, U	Other associated regulations and comments	Yes/No	If yes, how, specifically, is the requirement satisfied? If no, what is the recommendation to users?
Annex 11	11.1 Has the software or system been developed in accordance with an appropriate quality management system?	S, U	Annex 11 4.5 Brazil GMP 577 GAMP This is a shared responsibility between the system supplier and the user organization. The user should require the supplier to provide documented evidence that software is developed within the framework of a quality management system (QMS). 第二章原则 企业应当能够提供与供应商质量体系和审计信息相关的文件。	Yes	Cary WinUV Pharma is developed within the ISO 9001 Quality Management Standard (Ref. section 2.2 of the LSCA Quality Manual available at agilent.com/quality).
Brazil	11.2 Is there a formal agreement when the software supplier subcontracts software and maintenance services. Does the agreement include the contractor's responsibilities?	S, U	Brazil GMP 589 This is a shared responsibility between the system supplier and the user organization. The supplier must have such an agreement with the subcontractor, and the user must verify that the agreement is in place. 第二章原则 第四条企业应当注重计算机化系统供应商的管理，制定相应的操作规程。供应商提供产品或服务时（如安装、配置、集成、验证、维护、数据处理等），企业应当与供应商签订正式协议，明确双方责任。	Yes	Agilent requires formal agreements with all suppliers. (Ref. section 7.4 of the LSCA Quality Manual posted at agilent.com/quality).
ICH Q10	11.3 For outsourced (development and support) activities, is there a written agreement between the contract giver and contract acceptor?	S, U	ICHQ10, 2.7 c	N/A	Agilent requires formal agreements with all suppliers (Ref. section 7.4 of the LSCA Quality Manual posted at agilent.com/quality).
ICH Q10	11.4 Are the responsibilities and communication processes for quality related activities of the involved parties (contractors) defined?	S, U	ICHQ10, 2.7 c	N/A	Agilent defines responsibilities of all suppliers (Ref. section 7.4 of the LSCA Quality Manual posted at agilent.com/quality).
Part 11 11.10(i)	11.5 Is personnel developing and supporting software trained?	S, U	This is a shared responsibility between the system supplier and the user organization. The supplier must ensure its staff are trained, and the user should have assurance, for example, through audits, that software developers are trained and that this training is documented. 第三章人员 第五条计算机化系统的“生命周期”中所涉及的各种活动，如验证、维护、管理等，需要各相关的职能部门人员之间的紧密合作。在职责中涉及使用和管理计算机化系统的人员，应当接受相应的使用和管理培训。确保有适当的专业人员，对计算机化系统的设计、验证、安装和运行等方面进行培训和指导。	Yes	All Agilent personnel are required to be trained (Ref. section 6.0 of the LSCA Quality Manual posted at agilent.com/quality).

References

1. R. A. Botha, J. H. P. Eloff. "Separation of duties for access control enforcement in workflow environments" *IBM Systems Journal – End-to-end security* **40(3)**, 666-682 (2001).
2. U.S. Food and Drug Administration. CFR - Code of Federal Regulations Title 21. Title 21—Food and Drugs, Chapter I—Food and Drug Administration Department of Health and Human Services, Subchapter A—General. Part 11 Electronic Records; Electronics Signatures [Online] <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcr/CFRSearch.cfm?CFRPart=11> (accessed November 4, 2015).
3. European Commission Health and Consumers Directorate-General. Public Health and Risk Assessment. Pharmaceuticals. EudraLex. The Rules Governing Medicinal Products in the European Union. Volume 4. Good Manufacturing Practice. Medicinal Products for Human and Veterinary Use. Annex 11. Computerised Systems. [Online] http://ec.europa.eu/health/files/eudralex/vol-4/annex11_01-2011_en.pdf (accessed November 4, 2015).

For More Information

For more information on our products and services, visit our Web site at www.agilent.com/chem.

www.agilent.com/chem

Agilent shall not be liable for errors contained herein or for incidental or consequential damages in connection with the furnishing, performance, or use of this material.

Information, descriptions, and specifications in this publication are subject to change without notice.

© Agilent Technologies, Inc., 2016
Printed in the USA
November 16, 2016
5991-7268EN



Agilent Technologies